Eli Lilly’s Baqsimi (glucagon 3mg) Nasal Powder Receives FDA’s Approval for the Treatment of Severe Hypoglycemia
Eli Lilly Initiates P-III Study Evaluating Baricitinib in Hospitalized Patients with COVID-19
Shots:
- The FDA’s approval follows multiple studies with various age group evaluating baqsimi (glucagon, 3mg) nasal powder vs glucagon injection formulation in patients with diabetes aged 4yrs and older
- Collective study results demonstrated noninferiority data to glucagon injection formulation in raising blood glucose level after insulin-induced hypoglycemia, 100% patients reach treatment success i.e, increase in plasma glucose levels to ≥ 70 mg/dL or a ≥20 mg/dL rise in plasma glucose from nadir within 30 minutes post receiving glucagon
- Baqsimi is a dry nasal spray form of glucagon, ready to use with no reconstitution or priming required in a single, fixed 3 mg dose, to be absorbed in the nose and is expected to be available within one month in the US
Click here to read full press release/ article | Ref: Eli Lilly | Image: Amife